Skip to main content
Home Beijing 2022 Winter Games
  • News
  • Galleries
  • Medals
  • Schedule
Biochemistry
A woman reacts as a health worker waits to take her nasal swab sample to test for COVID-19 at a bus terminal in New Delhi, India, Wednesday, March 24, 2021. (AP Photo/Altaf Qadri)
New virus variant detected in India; experts urge caution

By Aniruddha Ghosal Mar. 24, 2021 11:43 AM EDT

FILE - In this Wednesday, March 10, 2021 file photo, Speaker of the House Nancy Pelosi, D-Calif., finishes the vote to approve a landmark $1.9 trillion COVID-19 relief bill, at the Capitol in Washington. On Friday, March 12, 2021, The Associated Press reported on stories circulating online incorrectly asserting the $1.9 trillion COVID-19 relief bill awards a $25 million bonus to members of the House of Representatives. There are several passages that cite $25 million in funding, but no mention of congressional pay raises or bonuses. (AP Photo/J. Scott Applewhite)
NOT REAL NEWS: A look at what didn't happen this week

The Associated Press Mar. 12, 2021 02:58 PM EST

In this Saturday, March, 14, 2020 photo provided by Regeneron, , left, and members of the company's infectious disease team pose for a photo as they celebrate their first discovery of potential antibodies to treat COVID-19. They had spent weeks drawing blood from early survivors across the globe and from mice with human-like immune systems - all to test thousands of potential treatments. (Regeneron via AP)
One company's quest for an antibody drug to fight COVID-19

By Marilynn Marchione Dec. 21, 2020 12:05 AM EST

FILE - In this Wednesday, Sept. 2, 2020 file photo, blood samples from volunteers participating in the last-stage testing of the COVID-19 vaccine by Moderna and the National Institutes wait to be processed in a lab at the University of Miami Miller School of Medicine in Miami. Creating vaccines and properly testing them less than a year after the world discovered a never-before-seen disease is incredible. But the two U.S. frontrunners are made in a way that promises speedier development may become the norm -- especially if they prove to work long-term as well as they have in early testing. (AP Photo/Taimy Alvarez, File)
Years of research laid groundwork for speedy COVID-19 shots

By Lauran Neergaard Dec. 07, 2020 10:54 AM EST

FILE - This electron microscope image made available and color-enhanced by the National Institute of Allergy and Infectious Diseases Integrated Research Facility in Fort Detrick, Md., in 2020, shows Novel Coronavirus SARS-CoV-2 virus particles, orange, isolated from a patient. One of COVID-19's scariest mysteries is why some people are mildly ill or have no symptoms and others rapidly die — and scientists are starting to unravel why. (NIAID/National Institutes of Health via AP)
Mild to severe: Immune system holds clues to virus reaction

By Lauran Neergaard And Candice Choi Sep. 30, 2020 01:22 PM EDT

German Health Minister Jens Spahn, left, and Science and Education Minister Anja Karliczek, right, arrive for a news conference about a german program to support the develop a COVID-19 vaccine in Berlin, Germany, Tuesday, Sept. 15, 2020.(AP Photo/Markus Schreiber, Pool)
Germany boosts own vaccine makers in race for COVID-19 jab

Sep. 15, 2020 07:38 AM EDT

FILE - In this Wednesday, June 24, 2020 file photo, a volunteer receives a COVID-19 test vaccine injection developed at the University of Oxford in Britain, at the Chris Hani Baragwanath hospital in Soweto, Johannesburg, South Africa. People on six continents are testing experimental shots as the race for a COVID-19 vaccine enters a defining summer, with even bigger studies poised to prove if any leading candidate really works - and possibly offer the public a reality check. (AP Photo/Siphiwe Sibeko)
Summer may decide fate of leading shots in vaccine race

By Lauran Neergaard Jun. 28, 2020 08:28 AM EDT

In this Wednesday, April 8, 2020 photo provided by the Center for Pharmaceutical Research, a participant in a COVID-19 coronavirus vaccine trial receives an injection in Kansas City, Mo. This early safety study, called a Phase 1 trial, is using a vaccine candidate developed by Inovio Pharmaceuticals. (Center for Pharmaceutical Research via AP)
Second US study for COVID-19 vaccine uses skin-deep shots

By Lauran Neergaard Apr. 08, 2020 05:06 PM EDT

AP Sports | © 2022 Associated Press
  • Privacy Policy
  • Terms of Use
  • AP News
  • AP Images
  • ap.org